The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | The benefit of allogeneic transplantation in patients with TP53-mutated AML
Mark Litzow, MD, Mayo Clinic, Rochester, MN, shares the results of a study that evaluated the outcomes of patients with TP53-mutated acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell transplantation (alloHSCT). The study showed that patients in first remission who received a transplant had better outcomes than those who didn’t, therefore demonstrating that alloHSCT should be offered to eligible patients with TP53-mutated AML. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen: Research Funding; Astellas: Research Funding; Novartis: Research Funding; Syndax: Research Funding; Jazz: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Actinium: Research Funding; Pluristem: Research Funding; Biosight: Consultancy, Other: Data Monitoring Board; Abbvie: Research Funding.
